The ROE as of December 2024 (TTM) for Myomo, Inc. (MYO) is -86.30%

According to Myomo, Inc.’s latest financial reports and current stock price. The company's current ROE is -86.30%. This represents a change of 308.29% compared to the average of -21.14% of the last 4 quarters.

Myomo, Inc. (MYO) Historical ROE (quarterly & annually)

How has MYO ROE performed in the past?

The mean historical ROE of Myomo, Inc. over the last ten years is -141.08%. The current -86.30% ROE has changed -38.83% with respect to the historical average. Over the past ten years (40 quarters), MYO's ROE was at its highest in in the September 2015 quarter at 81.69%. The ROE was at its lowest in in the June 2017 quarter at -188.19%.

Myomo, Inc. (MYO) ROE by Quarter and Year

Discovering the peaks and valleys of Myomo, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Myomo, Inc. (MYO) Average ROE

How has MYO ROE performed in the past?

The current ROE of Myomo, Inc. (MYO) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Myomo, Inc. (MYO) ROE vs. Peers

How is MYO’s ROE compared to its peers?

Myomo, Inc.’s ROE is greater than Sintx Technologies, Inc. (-140.68%), greater than ReShape Lifesciences Inc. (-179.83%), greater than Bone Biologics Corporation (-124.69%), greater than Ra Medical Systems, Inc. (-15.34%), greater than Tivic Health Systems, Inc. (-201.30%), greater than Bluejay Diagnostics, Inc. (-155.68%), greater than Vivos Therapeutics, Inc. (-335.03%), greater than Rapid Micro Biosystems, Inc. (-48.05%), greater than Talis Biomedical Corporation (-79.73%), greater than Nuwellis, Inc. (-26663.64%), less than Heart Test Laboratories, Inc. (-0.76%), greater than Nexalin Technology, Inc. (-187.62%), less than INVO Bioscience, Inc. (0%), greater than Motus GI Holdings, Inc. (-1832.08%), greater than IRIDEX Corporation (-192.95%), greater than Sight Sciences, Inc. (-47.28%), greater than STRATA Skin Sciences, Inc. (-91.63%), less than Aziyo Biologics, Inc. (124.47%), greater than enVVeno Medical Corporation (-48.73%),

Build a custom stock screener for Myomo, Inc. (MYO) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Myomo, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Myomo, Inc. (MYO) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Myomo, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.